# Circulating Extracellular Vesicles Downregulate NOS3 Expression in Endothelial Cells in Atrial Fibrillation

**Authors:** Nyozin Leimon, Anna Suzuki, Kohei Kawajiri, Giichi Nitta, Junji Yamaguchi, Satoshi Iwamiya, Satomi Hamada, Yasuhiro Shirai, Lai Wei, Masahiro Yamazoe, Kensuke Ihara, Tetsushi Furukawa, Tetsuo Sasano

PMC · DOI: 10.3390/jcm15041399 · 2026-02-10

## TL;DR

Atrial fibrillation increases circulating extracellular vesicles, which may impair endothelial function by reducing NOS3 expression.

## Contribution

This study identifies a novel mechanism linking atrial fibrillation to endothelial dysfunction via extracellular vesicles.

## Key findings

- Patients with AF have higher plasma EV concentrations and reduced endothelial function compared to those with SR.
- EVs from AF patients and rapidly paced cardiomyocytes reduce NOS3 mRNA expression in endothelial cells.
- Irregular pacing of cardiomyocytes increases EV release compared to regular pacing or non-paced cells.

## Abstract

Background: Atrial fibrillation (AF) is closely linked to endothelial dysfunction, yet its mechanisms remain unclear. Extracellular vesicles (EVs), including exosomes, are released by most cell types and mediate intercellular communication. We therefore investigated the role of EVs in endothelial dysfunction associated with AF. Methods: Vascular endothelial function in patients with sinus rhythm (SR), premature ventricular contractions (PVCs), or AF was assessed by peripheral arterial tonometry. Plasma-derived EVs were isolated from these three groups. Conditioned medium was collected from cultured cardiomyocytes (CMs), which were paced either regularly or irregularly at 1 Hz or 10 Hz or were non-paced, and EVs were subsequently isolated from the conditioned media. The isolated EVs were applied to endothelial cells (ECs), and mRNA levels of vasoactive genes were quantified. Results: The reactive hyperemia index (RHI) was significantly lower in patients with AF than in those with SR (RHI values: 1.98 in SR vs. 1.57 in AF, p = 0.049), whereas no significant decrease was observed in patients with PVCs, indicating endothelial dysfunction in AF. The plasma EV concentration was significantly higher in patients with AF than in those with SR. CMs subjected to 10 Hz irregular pacing released more EVs than non-paced cells and cells under 1 Hz regular pacing. When applied to ECs, EVs from patients with AF and from rapidly paced CMs significantly reduced NOS3 mRNA expression in vitro. Conclusions: Circulating EVs are increased in AF and could be associated with an impaired endothelial function in AF.

## Linked entities

- **Genes:** NOS3 (nitric oxide synthase 3) [NCBI Gene 4846]
- **Diseases:** atrial fibrillation (MONDO:0004981)

## Full-text entities

- **Genes:** Gapdh1 (Glyceraldehyde 3 phosphate dehydrogenase 1) [NCBI Gene 35728] {aka BEST:GH12586, CG12055, Dmel\CG12055, GA3PDH, GADPH, GAP}, EDN1 (endothelin 1) [NCBI Gene 1906] {aka ARCND3, ET1, HDLCQ7, PPET1, QME}, Fn1 (fibronectin 1) [NCBI Gene 14268] {aka E330027I09, Fn, Fn-1}, HSPA5 (heat shock protein family A (Hsp70) member 5) [NCBI Gene 3309] {aka BIP, GRP78, HEL-S-89n}, PANX1 (pannexin 1) [NCBI Gene 24145] {aka MRS1, OOMD7, OZEMA7, PX1, UNQ2529}, Apoa1 (apolipoprotein A-I) [NCBI Gene 11806] {aka Alp-1, Apoa-1, Brp-14, Ltw-1, Lvtw-1, Sep-1}, NOS3 (nitric oxide synthase 3) [NCBI Gene 4846] {aka EC-NOS, ECNOS, MYMY8, NOSIII, cNOS, eNOS}, APOA1 (apolipoprotein A1) [NCBI Gene 335] {aka AMYLD3, HPALP2, apo(a)}, Cd63 (CD63 antigen) [NCBI Gene 12512] {aka ME491, Tspan30}, CD63 (CD63 molecule) [NCBI Gene 967] {aka AD1, HOP-26, ME491, MLA1, OMA81H, Pltgp40}, nsl1 (non-specific lethal 1) [NCBI Gene 41911] {aka CG4699, Dmel\CG4699, E(nos), l(3)06536, l(3)S009413, wah}, CD81 (CD81 molecule) [NCBI Gene 975] {aka CVID6, S5.7, TAPA1, TSPAN28}
- **Diseases:** embolic (MESH:D004617), cardiac arrhythmia (MESH:D001145), SR (MESH:C563907), RHI (MESH:D006940), heart disease (MESH:D006331), blood stasis (MESH:D014647), PVCs (MESH:D018879), Fibrillation (MESH:D014693), endothelial (MESH:D005642), injury to (MESH:D014947), thrombus (MESH:D013927), HT (MESH:D006973), cardiovascular disease (MESH:D002318), Endothelial dysfunction (MESH:D014652), Atrial Fibrillation (MESH:D001281), DM (MESH:D003920), ischemic stroke (MESH:D002544)
- **Chemicals:** water (MESH:D014867), CO2 (MESH:D002245), L-glutamine (MESH:D005973), lipids (MESH:D008055), glutaraldehyde (MESH:D005976), norepinephrine (MESH:D009638), TBS-T (MESH:C027647), SDS (MESH:D012967), copper (MESH:D003300), polyvinylidene difluoride (MESH:C024865), NO (MESH:D009569), Chemi (-), penicillin (MESH:D010406), ethylenediaminetetraacetic acid (MESH:D004492), PKH26 (MESH:C070080), streptomycin (MESH:D013307), carbon (MESH:D002244)
- **Species:** Mus musculus (house mouse, species) [taxon 10090], Canis lupus familiaris (dog, subspecies) [taxon 9615], Homo sapiens (human, species) [taxon 9606]
- **Mutations:** T-786 C
- **Cell lines:** EA.hy926 — Homo sapiens (Human), Hybrid cell line (CVCL_3901), HL-1 — Mus musculus (Mouse), Transformed cell line (CVCL_0303)

## Figures

5 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12942163/full.md

---
Source: https://tomesphere.com/paper/PMC12942163